CHEOF (Cochlear) Net Current Asset Value: $5.26 (As of Dec. 2025) — 85% Below Median


CHEOF Cochlear Ltd CHEOF
62 GF Score
Price $86.08
GF Value $214.94
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Cochlear Net Current Asset Value?

Cochlear CHEOF 62 Net Current Asset Value is $5.26 as of Dec. 2025, which is 85% below its 10-year median of 36.24. GuruFocus rates CHEOF with a GF Score™ of 62/100 and a GF Value™ of $214.94 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 568 Medical Devices & Instruments companies, Cochlear ranks worse than 82.92% on this metric.

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

Cochlear's net current asset value per share for the quarter that ended in Dec. 2025 was $5.26.

The historical rank and industry rank for Cochlear's Net Current Asset Value or its related term are showing as below:

CHEOF' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 15.8   Med: 36.24   Max: 913.53
Current: 16.71

During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Cochlear was 913.53. The lowest was 15.80. And the median was 36.24.

CHEOF's Price-to-Net-Current-Asset-Value is ranked worse than
82.92% of 568 companies
in the Medical Devices & Instruments industry
Industry Median: 5.03 vs CHEOF: 16.71

Cochlear  (OTCPK:CHEOF) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


Cochlear Net Current Asset Value Related Terms


Cochlear Net Current Asset Value Historical Data

* Premium members only.

The historical data trend for Cochlear's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cochlear Net Current Asset Value Chart

Cochlear Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Net Current Asset Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.74 5.85 5.53 5.55 5.40

Cochlear Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Net Current Asset Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.90 5.55 4.76 5.40 5.26

CHEOF vs ABT, SYK, MDT: Net Current Asset Value Comparison

For the Medical Devices subindustry, Cochlear's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cochlear Price-to-Net-Current-Asset-Value vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cochlear's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where Cochlear's Price-to-Net-Current-Asset-Value falls into.


CHEOF
62GF Score
Cochlear Ltd CHEOF
Net Current Asset Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cochlear Net Current Asset Value Calculation

Cochlear's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Jun. 2025 is calculated as

Net Current Asset Value Per Share(A: Jun. 2025 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(922.396-569.466-0-0)/65.397
=5.40

Cochlear's Net Current Asset Value (NCAV) per share for the quarter that ended in Dec. 2025 is calculated as

Net Current Asset Value Per Share(Q: Dec. 2025 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(912.226-568.505-0-0)/65.398
=5.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Current Asset Value of $5.26 mean?
Cochlear (CHEOF) has a Net Current Asset Value of $5.26 as of Dec. 2025. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Cochlear and its competitors. This is 85% below median its historical median of 36.24. Over the past decade, Cochlear's Net Current Asset Value has ranged from 15.80 to 913.53. According to the industry distribution chart, Cochlear ranks #471 out of 568 companies in the Medical Devices & Instruments industry, placing it in the top 82.9%.
Is Cochlear's Net Current Asset Value too high?
Cochlear's current Net Current Asset Value of $5.26 is 85% below median its 10-year median of 36.24. Over the past 10 years, this metric has ranged from a low of 15.80 to a high of 913.53. The Medical Devices & Instruments industry median Net Current Asset Value is 5.03. Cochlear's value of $5.26 is 4.6% above this industry median. Based on the distribution chart, Cochlear ranks #471 out of 568 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Cochlear has a GF Score™ of 62/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cochlear's Net Current Asset Value compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Cochlear ranks #471 out of 568 companies for Net Current Asset Value. This places Cochlear in the lower half of its industry. The industry median Net Current Asset Value is 5.03. Cochlear's value of $5.26 is 4.6% above this benchmark. Historically, Cochlear's own Net Current Asset Value has ranged from 15.80 to 913.53 over the past decade. While the company's 10-year median is 36.24 vs. the industry median of 5.03, Cochlear has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Medical Devices & Instruments company?
The median Net Current Asset Value among Medical Devices & Instruments companies is 5.03, based on 568 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cochlear's current Net Current Asset Value of $5.26 is 4.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Cochlear and its competitors. For the Medical Devices & Instruments industry, the median Net Current Asset Value is 5.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cochlear's current Net Current Asset Value is $5.26, which is 85% below median its own 10-year median of 36.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cochlear stock overvalued right now?
Based on GuruFocus' analysis, Cochlear (CHEOF) is currently considered Significantly Undervalued. The stock's GF Value™ is $214.94, compared to a current price of $86.08 — trading 60% below its estimated fair value. The current Net Current Asset Value is $5.26, which is 85% below median its 10-year median of 36.24 and 4.6% above the Medical Devices & Instruments industry median of 5.03. Cochlear's overall GF Score™ is 62/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Cochlear (CHEOF), the current Net Current Asset Value is $5.26 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cochlear (CHEOF) Overvalued in 2026?

Based on GuruFocus' analysis, Cochlear stock appears to be undervalued. The current stock price of $86.08 is trading 60% below its estimated GF Value™ of $214.94. GuruFocus considers Cochlear to be Significantly Undervalued.

Key valuation signals for CHEOF:

  • Net Current Asset Value: $5.26 (85% below median its 10-year median of 36.24)
  • GF Value™: $214.94 vs. price of $86.08 (60% below fair value)
  • GF Score™: 62/100 with 2 warning signs
  • Industry Position: 4.6% above the Medical Devices & Instruments median (#471 of 568)

No single metric tells the full story. See the CHEOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cochlear Business Description

Address 1 University Avenue, Macquarie University, Sydney, NSW, AUS, 2109
Cochlear is the leading cochlear implant device manufacturer, with around 60% global market share. Developed markets contribute 80% of group revenue, where cochlear implants are the standard of care for children with severe-to-profound hearing loss. The company also actively targets the growing cohort of seniors in developed markets. Tender-oriented emerging markets contribute the remaining 20% of group revenue. Main products include cochlear implants, bone-anchored hearing aids, and associated sound processors. In fiscal 2025, 49% of revenue came from the Americas, 34% from Europe, the Middle East, and Africa, and 18% from the Asia-Pacific segment.
62GF Score

Get the complete analysis for CHEOF

Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$86.08
Price
$214.94
GF Value